Last reviewed · How we verify
Gla-100 (insulin glargine)
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Gla-100 (insulin glargine) |
|---|---|
| Also known as | LANTUS® |
| Sponsor | Sanofi |
| Drug class | Long-acting basal insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin glargine is a recombinant human insulin analog modified to have a prolonged duration of action (up to 24 hours). It binds to the insulin receptor on target tissues, facilitating glucose uptake into muscle and adipose tissue while suppressing hepatic glucose production. This provides steady basal insulin coverage for glycemic control in diabetes.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gla-100 (insulin glargine) CI brief — competitive landscape report
- Gla-100 (insulin glargine) updates RSS · CI watch RSS
- Sanofi portfolio CI